PED/PEA-15 is a recently identified cytosolic protein featuring ubiquitous expression (8, 6) . PED/PEA-15 has been shown to exert antiapoptotic action through distinct mechanisms. First, PED/PEA-15 inhibits formation of the deathinducing signaling complex (DISC) and caspase 3 activation by different apoptotic cytokines including FASL, tumor necrosis factor alpha, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (7, 16, 22) . At least in part, this action is accomplished through the death-effector-domain of PED/ PEA-15 upon PED/PEA-15 recruitment to the DISC (7, 16, 22) . Secondly, PED/PEA-15 inhibits the induction of different stress-activated protein kinases (SAPKs) triggered by growth factor deprivation, hydrogen peroxide, and anisomycin (5) . This action of PED/PEA-15 is exerted by the blocking of an upstream event in the SAPK activation cascade (5) and requires the interaction of PED with ERK1/2 (14, 17) .
PED/PEA-15 is phosphorylated at Ser 116 by calcium-calmodulin kinase II (CaMKII) (2) facilitating further phosphorylation by protein kinase C (PKC) at Ser 104 (23) . Thus, PED/ PEA-15 is present in the cell in the unphosphorylated (N), singly phosphorylated (Pa), and doubly phosphorylated (Pb) forms. Previous studies have shown that only the Pb form of PED/PEA-15 can be recruited to the DISC and inhibit TRAIL apoptotic signaling (31) . In addition, the antiapoptotic action of PED/PEA-15 requires PKC activity (7, 16, 22) , indicating that, in the cell, PED/PEA-15 function is regulated by phosphorylation. However, whether kinases different from PKC and CaMKII may trigger survival or antiapoptotic signals by regulating PED/PEA-15 function is currently unknown.
Akt/PKB is a serine/threonine kinase that plays a major role in transducing proliferative and survival signals intracellularly (15, 21, 25) . Akt/PKB has been demonstrated to phosphorylate a number of proteins involved in apoptotic signaling cascades, including the BCL2 family member BAD (12) , the protease caspase 9 (4), the Forkhead transcription factor FRLH (3), and p21
CipWAF1 (24) . Phosphorylation of these proteins prevents apoptosis through several different mechanisms. For instance, unphosphorylated BAD induces cell death by forming heterodimers with BCL-X L and generating BAX homodimers (12) . Upon activation of Akt/PKB, phosphorylated BAD promotes cell survival by binding the 14-3-3 protein, which prevents BAD association to BCL-X L (12) . At variance, in the case of p21 CipWAF1 , phosphorylation by Akt/PKB results in increased stability, promoting cell survival (24) .
The finding that PED/PEA-15 possesses a low-stringency Akt/PKB phosphorylation consensus led us to analyze the possibility that PED/PEA-15 may also represent a relevant Akt/ PKB substrate and that PED/PEA-15 phosphorylation by this kinase may regulate the antiapoptotic function of PED/PEA-15. In the present work we demonstrate that Akt, in addition to CaMKII, phosphorylates PED at Ser 116 in vitro and in vivo, regulating PED/PEA-15 function on cellular apoptosis. In part, Akt survival signaling may be mediated by PED/PEA-15.
MATERIALS AND METHODS
Materials. Media, sera, and antibiotics for cell culture and the Lipofectamine reagent were purchased from Invitrogen Ltd. (Paisley, United Kingdom). Rabbit polyclonal Akt antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif.), and phosphokinase antibodies were from New England Biolabs Inc. (Beverly, Mass.). PED/PEA-15 antibodies have been previously reported (6) . The HA-Akt, HA-Akt m⌬4-129 , and HA-Akt K179M plasmids were donated by G. L. Condorelli (La Sapienza University of Rome) and have been previously reported (13) , while recombinant Akt (rAkt) was purchased from Upstate Biotechnology Inc. (Lake Placid, N.Y.). Antisera against phospho-Serine 116 PED/PEA-15 (pSer 116 PED Ab) were prepared in rabbits by PRIMM (Milan, Italy) by using the PED/PEA-15 KLH-conjugated phosphopeptide NH 2 -CKDIIRQP(Sp)EEEI IKLAP-COOH. The specificity of this antiserum is shown in Fig. 2 in the present paper. The S 70 (HIFEISRRPDLL), S 104 (LTRIPSAKKYKD), and S 116 (IIRQP SEEIIK) PED/PEA-15 dodecapeptides were also synthesized by PRIMM. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) reagents were purchased from Bio-Rad (Richmond, Va.). Western blotting and ECL reagents and radiochemicals were from Amersham (Arlington Heights, Ill.). All other reagents were from Sigma (St. Louis, Mo.).
Plasmid preparation, cell culture, and transfection and apoptosis assays. The PED S1163G and PED S1043G mutant cDNAs were prepared by using a pcDNA3PED/PEA-15 cDNA and the site-directed mutagenesis kit by Stratagene (Heidelberg, Germany) according to the kit manufacturer's instructions. Sequences were confirmed by the Sanger method with the T7 sequencing kit (Pharmacia-LKB, Milan, Italy). Stable expression of the mutant cDNAs in 293 cells was achieved as reported in reference 5. The 293 cells expressing the wild-type PED/PEA-15 cDNA have been described in reference 16. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 100 IU of penicillin/ml, 100 IU of streptomycin/ml, and 2% L-glutamine in a humidified CO 2 incubator as reported in reference 5. Transient transfection of wild-type or mutant Akt cDNAs in these cells was accomplished by using the Lipofectamine method according to the manufacturer's instructions. Briefly, the cells were cultured in 60-mm-diameter dishes and incubated for 24 h in serum-free DMEM supplemented with 3 g of cDNA and 15 l of Lipofectamine reagent. An equal volume of DMEM supplemented with 20% fetal calf serum was then added for 5 h, followed by replacement with DMEM supplemented with 10% serum for 24 h before the assays. The U373MG human glioma cells were generously provided by C. Hao (University of Alberta, Edmonton, Canada). These cells were cultured and transfected as described in reference 16 .
Apoptosis was quantitated by using the Apoptosis ELISA Plus kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions.
Western blot analysis, PED/PEA-15 phosphorylation, and determination of Akt activity. For Western blotting, the cells were solubilized in lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 4 mM EDTA, 10 mM Na 4 PO 7 , 2 mM Na 3 VO 4 , 100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 100 mg of aprotinin/ml, 1 mM leupeptin) for 60 min at 4°C. Cell lysates were clarified at 5,000 ϫ g for 15 min. Solubilized proteins were then separated by SDS-PAGE and transferred onto 0.45-m-pore-size Immobilon-P membranes (Millipore, Bedford, Mass.). Upon incubation with the primary and secondary antibodies, immunoreactive bands were detected by ECL according to the manufacturer's instructions.
For studying phosphorylation of PED/PEA-15 in intact cells, 293 cells were transiently transfected with the different Akt constructs as indicated. After 24 h, the cells were rinsed with 150 mM NaCl, incubated in phosphate-and serum-free culture medium for 16 h at 37°C, and then further incubated for 8 h in this same medium supplemented with 200 Ci of [ 32 P]orthophosphate/ml. Insulin (final concentration, 100 nM) was then added, and the cells were rapidly rinsed with ice-cold saline followed by solubilization with 0.5 ml of lysis buffer per dish for 1 h at 4°C. Lysates were centrifuged at 5,000 ϫ g for 20 min, and solubilized proteins were precipitated with PED/PEA-15 antibodies, separated by SDS-PAGE, and revealed by autoradiography. In these assays, insulin action on PED phosphorylation was dose dependent, with half-maximal effect at 3 nM and maximal effect at 100 nM.
Akt activity was assayed in vitro as previously reported (11) . Briefly, 293 cells expressing either the wild-type or the mutant PED/PEA-15 cDNAs were solubilized in lysis buffer and lysates were clarified by centrifugation at 5,000 ϫ g for 20 min. Two hundred micrograms of the lysates were immunoprecipitated with Myc antibodies. The precipitates (or 2 g of recombinant PED) were incubated in a kinase reaction mixture containing 20 To this end, wild-type PED/PEA-15 cDNA was amplified by using the following two sets of primers: PED/PEA-15 5ЈEcoRI (5Ј-CCGGAATTCATGG TTGAGTACGGGACCCTC-3Ј) and PED/PEA-15 3ЈSalI (5Ј-GTCGACTCAG GCCTTCTTCGGTGGGGGGACC-3Ј). PED/PEA-15 cDNA was then cloned in the pGEX 4T1plasmid, and the sequence was confirmed by using the T7 sequencing kit. Lysates from Akt-transfected cells (500 g) or 0.4 g of recombinant Akt were incubated in the presence of 50 l of Sepharose-bound GST-PED/PEA-15 (approximately 2 g) for 2 h at 4°C. Beads were washed four times with TNT buffer (0.5% NP-40, 25 mM TRIS [pH 7.5], 30 mM MgCl 2 , 40 mM NaCl, 1 mM dithiothreitol) and then resuspended in Laemmli buffer followed by boiling for 4 min and centrifugation at 25,000 ϫ g for 3 min. Supernatants were analyzed by SDS-PAGE and blotting with Akt antibodies.
RESULTS
In vitro phosphorylation of PED/PEA-15 by Akt. PED/PEA-15 sequence analysis revealed the presence of a low-stringency Akt phosphorylation motif including the Ser 116 residue of PED/PEA-15 (Fig. 1A) . To verify the hypothesis that PED/ PEA-15 is an Akt substrate, we first expressed the hemagglutinin (HA)-tagged wild-type Akt (AktWT), the constitutively active HA-Akt m⌬4-129 (AktDϩ), and the inactive HA-Akt K179 M mutant cDNAs (AktD-) in 293 human embryonic kidney cells, because these cells express no detectable levels of endogenous PED/PEA-15. HA antibody-precipitated Akt from these cells was then tested for its ability to phosphorylate His-tagged recombinant PED/PEA-15 in vitro. SDS-PAGE analysis of the phosphorylation mixtures revealed that wild-type Akt induced PED/PEA-15 phosphorylation (Fig. 1B) . The constitutively active Akt induced fourfold-greater phosphorylation of PED/ PEA-15 than did wild-type Akt. In contrast, precipitated inactive Akt or HA precipitates from cells transfected with the empty vector (PC) did not. Blotting with PED/PEA-15 and HA antibodies revealed that these variations were not due to differences in the amounts of either PED/PEA-15 or Akt in the assays. In addition, blotting with specific antibodies toward the key Akt Serine activation site (serine 473 ; P-Akt) showed that the different phosphorylation levels of PED/PEA-15 closely paralleled the Akt activation state in each assay. Endogenous Akt precipitated from 293 cells upon stimulation with 100 nM insulin also induced a fivefold increase in PED/PEA-15 phosphorylation over the level observed with unstimulated cells (Fig. 1C) . Again, blotting with PED/PEA-15, Akt-1, and phospho-Akt antibodies indicated that the changes in PED/PEA-15 phosphorylation reflected differences in the activation state of Akt rather than different amounts of Akt or PED/PEA-15 in the assays. PED was indeed phosphorylated by Akt with a stoichiometry of 0.82 mol of phosphate/mol of recombinant PED, a value close to that observed in the case of CaMKII S1163G and 293 PEDWT cells; three independent clones of cells expressing the mutant and four expressing the wild-type PED were selected and characterized in detail). For control, three independent clones of cells expressing a second mutant cDNA of PED/PEA-15, featuring the Ser 104 3 Gly substitution, were also selected and used (PED S1043G cells; the Ser 104 3Gly mutation abolishes PED/ PEA-15 phosphorylation by PKC [23] ). Precipitates of these cells with PED/PEA-15 antibodies were phosphorylated by using HA precipitates from insulin-exposed cells expressing wild-type HA-Akt. In these assays, the Ser 116 3G mutant of PED/PEA-15 showed a fourfold-decreased phosphorylation by Akt compared to that of wild-type PED/PEA-15 ( Fig. 2A) . Phosphorylation of the Ser 104 3Gly mutant showed no significant difference from that of wild-type PED/PEA-15. In addition, blotting with antisera raised against a specific phosphoSerine 116 PED/PEA-15 peptide showed a 15-fold-decreased phosphorylation of the Ser 116 3G compared to that of the Ser 104 3G PED mutant or the wild-type PED. Also, incubation of recombinant active Akt with same amounts of PED/PEA-15 precipitated from cells expressing either the wild-type or the S 116 3G mutant PED/PEA-15 cDNAs showed 10-fold-decreased phosphorylation of the PED/PEA-15 mutant compared to that of the wild-type (Fig. 2B ). In this same assay, however, the active Akt phosphorylated the Ser 104 3Gly mutant of PED/PEA-15 at a level similar to that observed with wild-type PED/PEA-15. In vitro, the active Akt also phosphorylated twofold more effectively a synthetic dodecapeptide featuring the sequence of PED/PEA-15 surrounding Ser 116 (S 116 peptide) than a PED/PEA-15 dodecapeptide including Ser 70 (S 70 peptide; Fig. 2C ). An additional PED/PEA-15 dodecapeptide including Ser 104 (S 104 peptide) was phosphorylated to a level similar to that of the S 70 peptide. Thus, in vitro, Akt phosphorylates PED/PEA-15 on Ser 116 .
In vivo phosphorylation of PED by Akt. We also examined the phosphorylation of PED/PEA-15 by Akt in intact 293 PEDWT cells upon metabolic labeling with [ 32 P]orthophosphate. Incubation of 293 PEDWT cells with 100 nM insulin for 10 min stimulated PED/PEA-15 phosphorylation twofold above the basal level (Fig. 3A) . Overexpression of similar levels of wildtype or active Akt cDNAs also increased phosphorylation of PED/PEA-15 1.8-and 3.2-fold, respectively. The same results were obtained with two further independent clones of 293PEDWT cells (not shown), indicating that, at least in part, insulin may induce PED/PEA-15 phosphorylation through Akt activation. Consistent with the role of Akt in insulin-and serum-stimulated phosphorylation of PED, preincubation of 293 cells with the phosphatidylinositol (PI) 3-kinase blockers Wortmannin or LY294002 inhibited insulin-as well as serumstimulated phosphorylation of PED/PEA-15 by Ͼ70% (Fig.  3B ). These decreases in phosphorylation of PED were accompanied by a decrease of similar size in phosphorylation of the key site of BAD by Akt.
Since Akt phosphorylates PED/PEA-15 at Ser 116 in vitro, we asked whether Ser 116 is also phosphorylated in intact cells. To answer this question, we compared PED/PEA-15 phosphorylation in the 293 PEDWT , the 293 S1163G , and the 293 S1043G 32 P]ATP. The phosphorylation reaction was terminated with Laemmli buffer, and samples were subjected to SDS-PAGE and autoradiography. For control, the gels were also blotted with PED/PEA-15, HA, and Akt phosphoserine 473 antibodies (P-Akt), as indicated. (C) 293 cells were stimulated with 100 nM insulin for 10 min and solubilized as described in Materials and Methods, and lysates were immunoprecipitated with Akt1 antibodies. Precipitated Akt was incubated with recombinant PED/PEA-15, and PED/PEA-15 phosphorylation was assayed as described above. For control, the gels were blotted with PED/PEA-15, Akt-1, and P-Akt antibodies. The autoradiographs shown are representative of three (B) and four (C) independent experiments. (Fig. 3D) . Importantly, insulin-induced phosphorylation of PED at (Fig. 4C) . PED/PEA-15-GST incubation of extracts from cells expressing constitutively active, kinase-defective, and wild-type HA-Akt cDNAs followed by Akt blotting revealed that the mutant, the wild-type, and the endogenous Akt equally bound to PED/PEA-15 (Fig. 4D) . Direct blotting of the cell extract with HA antibodies showed similar levels of transfected Akt in the cells. It appeared therefore that the formation of the PED/PEA-15-Akt complex is independent of Akt activity.
PED exerts a broad antiapoptotic action (5, 7, 16, 22) . The finding that PED/PEA-15 binds and is phosphorylated by Akt led us to hypothesize that the antiapoptotic action of PED/ PEA-15 may be contributed by activation of Akt signaling, or it may be regulated by phosphorylation by Akt, or both. To answer these questions, we compared the serum activation of Akt in the 293 PEDWT cells with that in cells transfected with the empty plasmid (293 PC ). As shown in Fig. 5A , there was no difference between the phosphorylation levels of the key Akt serine activation sites in these two cell types. Also, BAD phosphorylation by Akt featured no difference in the 293 PEDWT and the 293 PC cells (Fig. 5B) , indicating that Akt activity is not (5), cell treatment with the MEK inhibitor PD98059 also induced an increase in apoptosis of almost fourfold. The effects of Wortmannin, PD98059, and BDM were more pronounced than in untransfected cells (P Ͻ 0.001 by t test analysis), indicating an important role of PED/PEA-15 in their elicitation. The 293 S1163G and 293 S1043G cells exhibited, respectively, nine-and fivefold-higher basal rates of apoptosis compared to the 293 PEDWT cells (P Ͻ 0.001). Wortmannin had no further effect on apoptosis in the 293 S1163G cells, whereas it increased the apoptosis in the 293 S1043G cells threefold. In contrast, BDM slightly increased apoptosis in the 293 S1163G cells (40%; P Ͻ 0.05) but had no effect at all in those expressing the Ser 1043G mutant. PD98059 increased apoptosis by 40% and twofold, respectively, in the 293 S1163G and the 293 S1043G cells. Thus, Akt as well as PKC phosphorylations exerted an important role in regulating PED function. Akt action on PED stability in 293 cells. To elucidate the significance of phosphorylation by Akt for PED/PEA-15 function, we tested the possibility that Akt phosphorylation affects the half-life of PED/PEA-15 in the cells. We first compared the expression levels of wild-type PED/PEA-15 in cells maintained in the presence and in the absence of serum, when phosphorylation of the key Akt activation site is maximal and undetectable, respectively. As shown in Fig. 6A , PED/PEA-15 levels were fivefold higher in the cells exposed to serum than in the starved cells. Also, the effect of serum on the expression level of PED/PEA-15 was reduced threefold by Wortmannin, in parallel with the effect of serum on Akt phosphorylation. Very similar results were obtained in the presence of 100 nM insulin instead of serum (data not shown). More compelling, in the serum-starved cells, expression of the constitutively active Akt mutant resulted in PED/PEA-15 expression levels comparable to those measured in cells maintained in the presence of serum. In addition, both the effect of serum and that of the active Akt on PED/PEA-15 levels were absent in the 293 S1163G cells, demonstrating the role of Akt phosphorylation in determining the intracellular levels of PED/PEA-15.
Next, we directly examined whether Akt phosphorylation may increase the stability of PED/PEA-15. We incubated 293 PEDWT and 293 S1163G cells with the protein synthesis inhibitor cycloheximide. We then compared the degradation rates of PED/PEA-15 in the two cell types. As shown in Fig.  6B , in the 293 PEDWT cells, almost 50% of the initial levels of PED/PEA-15 were still present after 6 h of incubation with cycloheximide. The disappearance of PED/PEA-15 was much faster in the 293 S1163G cells, since in these cells 50% of PED/ PEA-15 levels became undetectable within only 1 h. Again, the difference in PED stability in the 293 PEDWT and the 293 S1163G cells was confirmed in two other clones of each cell line (data not shown). Earlier reports showed that PKC phosphorylation at Ser 104 depends on previous phosphorylation at Ser 116 (23) . Thus, phosphoserine 104 might also contribute to PED stability. Accordingly, wild-type PED stability also decreased when PKC activity was blocked by BDM, although less evidently than with the Ser 116 3Gly mutant. Hence, upon treatment with BDM, 50% of the initial levels of wild-type PED were present after 3 h of incubation with cycloheximide. Consistent with the permissive role of Ser 116 phosphorylation on that of Ser 104 (23) , treatment with BDM caused only a slight further increase in the degradation rate of PED S1163G .
Action of Akt on PED stability and function in human glioma cells. To further address the significance of PED phosphorylation by Akt, we have blocked Akt activity in the U373MG human glioma cell line. These cells feature high levels of PED determining resistance to the apoptotic cytokine TRAIL (16, 31) . Similar to what was observed with the 293 cells, in the U373MG glioma cells preincubation with either Wortmannin or LY294002 caused an 80% increase in apoptosis (P Ͻ 0.001; Fig. 7 ). This induction of apoptosis was accompanied by a Ͼ3-fold decrease in PED phosphorylation at Ser 116 and in the cellular levels of PED (Fig. 7, top) . Interestingly, both treatment with Wortmannin and treatment with LY294002 rescued sensitivity to TRAIL apoptosis. Wortmannin and LY294002 also reduced Akt activity as well as PED recruitment to TRAIL-induced DISC by Ͼ80% (data not shown), supporting the major role of this kinase in controlling the cellular function of PED in the glioma as well as in other cells.
DISCUSSION
PED/PEA-15 is a recently identified protein featuring a broad antiapoptotic function (5, 7, 16, 22) . PED/PEA-15 inhibits the apoptotic signal of FasL, tumor necrosis factor alpha, and TRAIL (7, 16, 22) and also blocks apoptosis following the activation of several SAPKs (6) . Previous work in our own as well as in other laboratories has shown that phosphorylation by PKC plays an important role in enabling the antiapoptotic function of PED/PEA-15 (7, 16, 22) . In the present paper we demonstrate that PED/PEA-15 phosphorylation by Akt also regulates PED/PEA-15 control of cell apoptosis.
We (1) . In contrast, the 5-aminoacid region of PED/PEA-15 upstream from Ser 116 exhibits only a single Arg residue. The same structural feature has been reported for the Akt Ser substrates of CREB (10) and of the 14-3-3 scaffold protein (27) . In the case of PED/PEA-15, we showed that PED/PEA-15 directly binds to Akt. The binding is independent of Akt activity, as it effectively occurs to both constitutively active and inactive Akt mutants as well as to wild-type Akt. In addition, PED/PEA-15 binds Akt with an affinity similar to that exhibited for ERK1, a known PED/PEA-15 ligand (14, 17) (data not shown). It is possible, therefore, that in the cell PED/PEA-15 recruits Akt and that this facilitates PED/PEA-15 phosphorylation by the kinase.
When expressed in 293 cells, the S 116 3G mutant PED/PEA-15 showed an almost twofold decrease in antiapoptotic function compared to wild-type PED/PEA-15. In 293 cells, PED inhibition of apoptosis requires PED activation of ERKs (5). However, reduced antiapoptotic function of the Ser 116 3G mutant did not appear to depend on changes in its interaction with ERKs, as ERK activation levels were not different in cells expressing the mutant and in wild-type cells (data not shown). Interestingly, a pharmacological blocking of wild-type PED/ PEA-15 phosphorylation at Ser 116 was accompanied by a significant increase in 293 cell apoptosis, even in the presence of serum. These findings suggest that, at least in the 293 cells, PEDWT and 293 S1163G cells were deprived of serum for 14 h and then further incubated with 40 g of cycloheximide/ml for the indicated times in the absence or the presence of 100 nM BDM. Cells were then solubilized, and 100 g of cell proteins were subjected to SDS-PAGE followed by blotting with PED/PEA-15 antibodies, ECL, and autoradiography. (C) Autoradiographs were analyzed by laser densitometry. Each data point is the mean Ϯ standard deviation of four independent experiments, one of which is shown in panel B. Akt regulates a number of cellular functions including cell survival (25) . Different substrates are phosphorylated by Akt and converted into survival proteins (3, 4, 12, 24) . This function, in turn, is accomplished by regulating protein-protein interaction (12) , by affecting protein localization (3) or protein stability (24) . In the present work, we show that Akt phosphorylation increases the stability of PED/PEA-15 in the cell. Hence, PED/PEA-15 levels are low in cells subjected to serum starvation, when Akt activity is inhibited, and in cells subjected to pharmacological blocking of the PI 3-K/Akt pathway. PED/ PEA-15 cellular levels increase upon expression of a constitutively active Akt mutant. In addition, we report that the S 116 3G PED/PEA-15 mutant features reduced stability compared to that of wild-type PED/PEA-15. At variance with wildtype PED/PEA-15, the S 116 3G mutant is unaffected by Akt. Thus, at least in part, Akt regulates PED protein stability and antiapoptotic function by phosphorylating PED/PEA-15 at Ser 116 . PED/PEA-15 degradation is blocked by treatment of the cells with the proteasome inhibitor lactacystin, suggesting that PED/PEA-15 intracellular levels are regulated by the ubiquitin pathway (data not shown). Whether this hypothesis holds and whether PED/PEA-15 ubiquitination is, in turn, inhibited by Akt phosphorylation is currently being investigated in our laboratory.
The PED/PEA-15 gene is amplified in human breast cancer (20) as well as in other tumors and PED/PEA-15 overexpression may have a role in skin carcinogenesis (S. Santopietro and J. Portella, personal communication). Akt is also upregulated in a number of human cancers (26, 28, 29) . In this work, we demonstrated that PED/PEA-15 is a substrate for Akt and obtained evidence that Akt phosphorylation and stabilization of PED/PEA-15 is a previously unrecognized mechanism involved in Akt survival signaling. Simultaneous increases in PED/PEA-15 cellular levels and Akt activity might function cooperatively in tumorigenesis and/or tumor progression in humans. FIG. 7 . Akt action on PED function in U373MG cells. U373MG cells were preincubated with 100 M LY294002 or 50 nM Wortmannin for 3 h and then exposed to 300 ng of TRAIL/ml, as indicated. Apoptosis was quantitated by evaluating the level of DNA fragmentation by using the ELISA Plus detection kit as described in Materials and Methods. Some of the cells were also solubilized and Western blotted with either PED/PEA- 15 
